Literature DB >> 24751611

Chloroquine synergizes sunitinib cytotoxicity via modulating autophagic, apoptotic and angiogenic machineries.

Amal Kamal Abdel-Aziz1, Samia Shouman2, Ebtehal El-Demerdash3, Mohamed Elgendy4, Ashraf B Abdel-Naim5.   

Abstract

Tyrosine kinases play a pivotal role in oncogenesis. Although tyrosine kinase inhibitors as sunitinib malate are used in cancer therapy, emerging studies report compromised cytotoxicity when used as monotherapy and thus combinations with other anti-cancer agents is recommended. Chloroquine is a clinically available anti-malarial agent which has been shown to exhibit anti-cancer activity. In the current study, we questioned whether chloroquine can modulate sunitinib cytotoxicity. We found that chloroquine synergistically augmented sunitinib cytotoxicity on human breast (MCF-7 and T-47D), cervical (Hela), colorectal (Caco-2 and HCT116), hepatocellular (HepG2), laryngeal (HEp-2) and prostate (PC3) cancer cell lines as indicated by combination and concentration reduction indices. These results were also consistent with that of Ehrlich ascites carcinoma (EAC) Swiss albino mice models as confirmed by tumor volume, weight, histopathological examination and PCNA expression. Sunitinib induced autophagy via upregulating beclin-1 expression which was blocked by chloroquine as evidenced by accumulated SQTSM1/p62 level. Furthermore, chloroquine augmented sunitinib-induced apoptosis by decreasing survivin level and increasing caspase 3 activity. Chloroquine also enhanced the antiangiogenic capacity of sunitinib as indicated by decreased CD34 expression and peritoneal/skin angiogenesis. Sunitinib when combined with chloroquine also increased reactive nitrogen species production via increasing inducible nitric oxide synthase expression and nitric oxide level whilst reduced reactive oxygen species production by increasing GSH level, activities of glutathione peroxidase and catalase and reducing lipid peroxides compared to sunitinib-only treated group. Taken together, these findings suggest that chloroquine enhanced sunitinib cytotoxicity in a synergistic manner via inducing apoptosis while switching off autophagic and angiogenic machineries. Nevertheless, further studies are required to elucidate the efficacy and safety profile of such combination.
Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Angiogenesis; Apoptosis; Autophagy; Chloroquine; Oxidative stress; Sunitinib

Mesh:

Substances:

Year:  2014        PMID: 24751611     DOI: 10.1016/j.cbi.2014.04.007

Source DB:  PubMed          Journal:  Chem Biol Interact        ISSN: 0009-2797            Impact factor:   5.192


  34 in total

1.  Resistance to sunitinib in renal clear cell carcinoma results from sequestration in lysosomes and inhibition of the autophagic flux.

Authors:  Sandy Giuliano; Yann Cormerais; Maeva Dufies; Renaud Grépin; Pascal Colosetti; Amine Belaid; Julien Parola; Anthony Martin; Sandra Lacas-Gervais; Nathalie M Mazure; Rachid Benhida; Patrick Auberger; Baharia Mograbi; Gilles Pagès
Journal:  Autophagy       Date:  2015       Impact factor: 16.016

2.  Autophagy Inhibition Enhances Sunitinib Efficacy in Clear Cell Ovarian Carcinoma.

Authors:  Lindsay DeVorkin; Matthew Hattersley; Paul Kim; Jenna Ries; Jaeline Spowart; Michael S Anglesio; Samuel M Levi; David G Huntsman; Ravi K Amaravadi; Jeffrey D Winkler; Anna V Tinker; Julian J Lum
Journal:  Mol Cancer Res       Date:  2017-02-09       Impact factor: 5.852

3.  Dual modulation of MCL-1 and mTOR determines the response to sunitinib.

Authors:  Mohamed Elgendy; Amal Kamal Abdel-Aziz; Salvatore Lorenzo Renne; Viviana Bornaghi; Giuseppe Procopio; Maurizio Colecchia; Ravindran Kanesvaran; Chee Keong Toh; Daniela Bossi; Isabella Pallavicini; Jose Luis Perez-Gracia; Maria Dolores Lozano; Valeria Giandomenico; Ciro Mercurio; Luisa Lanfrancone; Nicola Fazio; Franco Nole; Bin Tean Teh; Giuseppe Renne; Saverio Minucci
Journal:  J Clin Invest       Date:  2016-11-28       Impact factor: 14.808

Review 4.  Autophagy, a double-edged sword in anti-angiogenesis therapy.

Authors:  Jiatao Liu; Lulu Fan; Hua Wang; Guoping Sun
Journal:  Med Oncol       Date:  2015-12-29       Impact factor: 3.064

5.  Antagonistic effects of chloroquine on autophagy occurrence potentiate the anticancer effects of everolimus on renal cancer cells.

Authors:  A Grimaldi; D Santini; S Zappavigna; A Lombardi; G Misso; M Boccellino; V Desiderio; P P Vitiello; G Di Lorenzo; A Zoccoli; F Pantano; M Caraglia
Journal:  Cancer Biol Ther       Date:  2015-04-11       Impact factor: 4.742

Review 6.  Clinical Trials of Antiangiogenesis Therapy in Recurrent/Persistent and Metastatic Cervical Cancer.

Authors:  Jill K Alldredge; Krishnansu S Tewari
Journal:  Oncologist       Date:  2016-03-29

7.  Macroautophagy is dispensable for growth of KRAS mutant tumors and chloroquine efficacy.

Authors:  Christina H Eng; Zuncai Wang; Diane Tkach; Lourdes Toral-Barza; Savuth Ugwonali; Shanming Liu; Stephanie L Fitzgerald; Elizabeth George; Elizabeth Frias; Nadire Cochran; Rowena De Jesus; Gregory McAllister; Gregory R Hoffman; Kevin Bray; LuAnna Lemon; Judy Lucas; Valeria R Fantin; Robert T Abraham; Leon O Murphy; Beat Nyfeler
Journal:  Proc Natl Acad Sci U S A       Date:  2015-12-17       Impact factor: 11.205

8.  Acquired tumor cell resistance to sunitinib causes resistance in a HT-29 human colon cancer xenograft mouse model without affecting sunitinib biodistribution or the tumor microvasculature.

Authors:  Kristy J Gotink; Henk J Broxterman; Richard J Honeywell; Henk Dekker; Richard R de Haas; Kiersten M Miles; Remi Adelaiye; Arjan W Griffioen; Godefridus J Peters; Roberto Pili; Henk M W Verheul
Journal:  Oncoscience       Date:  2014-12-15

Review 9.  Anticancer Effect of AntiMalarial Artemisinin Compounds.

Authors:  A K Das
Journal:  Ann Med Health Sci Res       Date:  2015 Mar-Apr

10.  PD-1-siRNA Delivered by Attenuated Salmonella Enhances the Antitumor Effect of Chloroquine in Colon Cancer.

Authors:  Shuya Lu; Jianhui Gao; Huijie Jia; Yang Li; Yongbin Duan; Fuyang Song; Zhiang Liu; Shuai Ma; Mingyong Wang; Tiesuo Zhao; Jiateng Zhong
Journal:  Front Immunol       Date:  2021-07-06       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.